Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome.
OBJECTIVE
To clarify whether the metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein (HDL) are altered in patients with polycystic ovary syndrome (PCOS).


METHODS
Case-control study.


METHODS
Endocrinology clinics.


METHODS
Eight normal-weight (NW) and 15 obese (Ob) patients with PCOS were compared with 10 NW and 10 Ob women without PCOS paired for age and body mass index.


METHODS
Determination of triglyceride-rich lipoprotein metabolism and lipid transfer to HDL.


METHODS
Participants were injected triglyceride-rich emulsions labeled with (14)C-cholesteryl esters and (3)H-triglycerides and the fractional clearance rate (FCR, in min(-1)) of labels was determined. Lipid transfer from artificial nanoemulsions to HDL was performed by incubating radioactively labeled lipid nanoemulsions with plasma during 1 hour, followed by radioactive counting of HDL-containing supernatant after chemical precipitation.


RESULTS
Lipolysis estimated by triglyceride FCR was equal in PCOS groups (NW = 0.043 +/- 0.032, Ob = 0.033 +/- 0.009) and respective controls (NW = 0.039 +/- 0.015, Ob = 0.044 +/- 0.019). However, the remnant removal as estimated by cholesteryl ester FCR was reduced in both PCOS groups (NW = 0.005 +/- 0.006, Ob = 0.005 +/- 0.005) compared with controls (NW = 0.016 +/- 0.006, Ob = 0.011 +/- 0.072). Lipid transfer rates were not different among groups, but triglyceride transfer rates were positively correlated with homeostasis model assessment estimate of insulin resistance in PCOS.


CONCLUSIONS
PCOS patients showed decreased removal of atherogenic remnants even when fasting glucose was <100 mg/dL. This reinforces the usefulness of the measures taken to prevent cardiovascular events in PCOS patients.
Rocha
Michelle P
MP
Endocrinology Section, Medical School Hospital, University of São Paulo, São Paulo, Brazil.
Maranhão
Raul C
RC
Seydell
Talita M
TM
Barcellos
Cristiano R G
CR
Baracat
Edmundo C
EC
Hayashida
Sylvia A Y
SA
Bydlowski
Sérgio P
SP
Marcondes
José A M
JA
D000328:Adult; D000367:Age Factors; D001692:Biological Transport / Q000502:physiology; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D005217:Fat Emulsions, Intravenous; D005260:Female; D006801:Humans; D056865:Ideal Body Weight / Q000502:physiology; D007333:Insulin Resistance / Q000502:physiology; D050356:Lipid Metabolism / Q000502:physiology*; D008075:Lipoproteins, HDL / Q000097:blood / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood; D016555:Matched-Pair Analysis; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000378:metabolism; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics; D055815:Young Adult
D002250:Carbon Radioisotopes; D005217:Fat Emulsions, Intravenous; D008075:Lipoproteins, HDL; D014280:Triglycerides; D007986:Luteinizing Hormone